PLK1在不同TP53基因型宫颈癌细胞中的作用OA

Objective To investigate the role of Polo-like kinase 1(PLK1)in cervical cancer cells with different TP53 genotypes.Methods C33a cells(TP53 mutant type)and SiHa cells(TP53 wild type)were treated with the PLK1 inhibitor GSK461364 at 0 nmol/L(control group),2.5 nmol/L(low-concentration group),or 5 nmol/L(high-concentration group)for 24 h.Cell proliferation,cell cycle distri-bution,stemness,and the expression of cell cycle-related proteins were assessed.GEPIA and TCGA databases were used to analyze PLK1 expression and its clinical significance.Results GSK461364 inhibited C33a cell proliferation,induced G2-phase arrest in both cell lines,and attenuated spheroid formation capacity.In C33a cells,both the low-and high-concentration groups showed significantly decreased expression of P-cdc25c,cdc25c,and E2F-1(P<0.05),whereas FoxO1 expression was significantly decreased only in the high-concen-tration group(P<0.05).In SiHa cells,the high-concentration group showed significantly downregulated expression of P-cdc25c,E2F-1,and FoxO1(P<0.05).PLK1 was highly expressed in cervical cancer.Patients with low PLK1 or FoxO1 expression exhibited significantly longer progression-free survival than those with high expression(P<0.05).Conclusion PLK1 inhibition suppressed cell proliferation,induced cell cycle arrest,and impaired spheroid formation in cervical cancer cells,with differential effects according to TP53 genotype.